Adrenal cortex neoplasm
MONDO:0036591A benign or malignant (primary or metastatic) neoplasm affecting the adrenal cortex. (NCI05)
Also known as: adrenal cortex neoplasm, adrenal cortex tumor, adrenal cortex tumour, adrenocortical neoplasm, adrenocortical tumor, adrenocortical tumour, neoplasm of adrenal cortex, tumor of adrenal cortex
1491 clinical trials for this condition and its sub-types, 11 tagged with Adrenal cortex neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Adrenal cortex neoplasm
-
Malignant tumor of adrenal cortex 0 trials · 42 incl. sub-types
1 sub-type
- Adrenal cortex carcinoma 42 trials Sub-types →
-
Adrenal cortex adenoma 12 trials · 19 incl. sub-types
4 sub-types
-
Familial hyperaldosteronism type II 0 trials
Most studied deeper sub-types
-
New hope for liver metastases: immune booster combined with targeted chemo
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Phase 1/2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take aim at childhood cancers
Disease control Recruiting nowThis early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to shrink Hard-to-Treat adrenal tumors
Disease control Recruiting nowThis phase II trial is testing whether combining cabozantinib (a drug that blocks tumor growth and blood vessel formation) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with advanced adrenocortical carcinoma. The stud…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Global effort to unlock secrets of rare childhood cancer
Knowledge-focused Recruiting nowThis study collects medical and family history from children and teens with adrenocortical tumors, a rare cancer. Researchers also study tumor samples to learn about genetic factors like the TP53 gene. The goal is to better understand the disease and improve care worldwide.
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists dive deep into DNA of Kids' cancers to unlock secrets
Knowledge-focused Recruiting nowThis study collects tumor and blood samples from 1,000 children with solid cancers like neuroblastoma and sarcoma. Researchers will analyze the genetic makeup and immune response of these tumors to better understand how they grow and resist treatment. The goal is to gather knowle…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC